Clinical Trials Logo

Richter Transformation clinical trials

View clinical trials related to Richter Transformation.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05828589 Recruiting - Clinical trials for Refractory Chronic Lymphocytic Leukemia

A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

Start date: June 20, 2023
Phase: Phase 1
Study type: Interventional

This study is testing the safety and tolerability of BGB-21447 monotherapy in participants with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study aims to determine the maximum tolerated dose (MTD), maximum adminstered dose (MAD), recommended Phase 2 dose (RP2D), and pharmacokinetic profile of the drug. Additionally, preliminary antitumor activity will be characterized. The study is divided into 2 main parts: Part 1 "Monotherapy Dose Finding" and Part 2 "Monotherapy Dose Expansion."

NCT ID: NCT05107674 Recruiting - Gastric Cancer Clinical Trials

A Study of NX-1607 in Adults With Advanced Malignancies

Start date: September 29, 2021
Phase: Phase 1
Study type: Interventional

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

NCT ID: NCT04771572 Recruiting - Multiple Myeloma Clinical Trials

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Start date: August 23, 2021
Phase: Phase 1
Study type: Interventional

This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.